The recent paradigm shift in diabetes therapy [14] claims that the adoption of newer drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotrasporter-2 (SGLT-2) inhibitors, for the management of type 2 diabetes may improve the poor cardiovascular outlook of the diabetic patient. This evidence concerns the gene SLC5A2 and diabetes mellitus.